Package Leaflet: Information for the Patient
Paxlovid 150mg+100mg film-coated tablets
nirmatrelvir + ritonavir
This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
Paxlovid contains two active substances: nirmatrelvir and ritonavir in two different tablets. Paxlovid is an antiviral medicine used to treat adults with COVID-19 who do not require supplemental oxygen and who are at high risk of progressing to severe illness.
COVID-19 is caused by a virus called coronavirus. This medicine works by stopping the virus from multiplying in the cells and this stops the virus from multiplying in the body. This can help your body get rid of the viral infection and may prevent you from developing a severe illness.
You should consult a doctor if you do not feel better after 5 days or if you feel worse.
.
Do not take Paxlovid
Warnings and precautions
Allergic reactions
Allergic reactions, including serious allergic reactions (known as “anaphylaxis”) and severe skin reactions (known as “toxic epidermal necrolysis” and “Stevens-Johnson syndrome”), can occur in people taking this medicine, even after a single dose. Stop taking this medicine and call your doctor right away if you have any of the following symptoms of an allergic reaction:
Liver disease
Tell your doctor if you have or have had liver disease. Abnormalities of liver enzymes, hepatitis, and jaundice have occurred in patients receiving ritonavir.
Kidney disease
Tell your doctor if you have or have had kidney disease.
High blood pressure
Tell your doctor if you have high blood pressure. Your doctor may need to check your blood pressure before you take this medicine and while you are taking this medicine. Cases of high blood pressure have been reported in people taking this medicine, especially in older people.
Risk of developing HIV-1 resistance
If you have an untreated or uncontrolled HIV infection, Paxlovid may cause some HIV medicines to not work as well in the future.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years of age because this medicine has not been studied in children and adolescents.
Other medicines and Paxlovid
There are other medicines that may not be taken with Paxlovid. Tell your doctor(s) or pharmacist if you are taking, have recently taken, or might take any other medicines:
Many medicines interact with Paxlovid. Keep a list of your medicines to show your doctor(s) and pharmacist. Do not start taking a new medicine without talking to your doctor(s) first. Your doctor(s) may tell you if it is safe to take Paxlovid with other medicines.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
There is not enough information to guarantee that the use of Paxlovid is safe during pregnancy. If you are pregnant, do not take this medicine unless your clinical situation requires this treatment. It is recommended that you abstain from sexual activity or use a contraceptive method while taking this medicine and, as a precaution, for 7 days after completing treatment. If you are taking oral contraceptives, since this medicine may reduce the effectiveness of this medicine, it is recommended to use a condom or another non-hormonal contraceptive method. Your doctor will inform you of the duration of this adjustment in contraceptive measures.
A small amount of Paxlovid passes into breast milk. You should not breastfeed your baby while taking this medicine and, as a precaution, for 48 hours after completing treatment.
Driving and using machines
Paxlovid is not expected to affect your ability to drive or use machines.
Paxlovid contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Paxlovid contains sodium
The nirmatrelvir and ritonavir tablets contain less than 1 mmol of sodium (23 mg) per dose; this is essentially “sodium-free”.
Take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist again
Paxlovid consists of 2 medicines: nirmatrelvir and ritonavir.
Treatment lasts for 5 days.
Swallow the tablets whole. Do not chew, break, or crush the tablets. This medicine can be taken with or without food.
Recommended dose
Without kidney disease or with mild kidney disease
If you DO NOT have any kidney disease or have MILD kidney disease, the recommended dose is 2 pink tablets of nirmatrelvir with 1 white tablet of ritonavir, by mouth, twice a day (in the morning and at night).
Moderate kidney disease
If you have MODERATE kidney disease, the recommended dose is 1 pink tablet of nirmatrelvir with 1 white tablet of ritonavir, by mouth, twice a day (in the morning and at night).
Severe kidney disease
If you have SEVERE kidney disease, the recommended dose is 2 pink tablets of nirmatrelvir with 1 white tablet of ritonavir, by mouth, once on DAY 1, and then 1 pink tablet of nirmatrelvir with 1 white tablet of ritonavir, by mouth, once a day on DAYS 2 to 5.
If you take more Paxlovid than you should
If you take too much of this medicine, call your healthcare provider or go to the emergency room of the nearest hospital right away.
If you forget to take Paxlovid
If you miss a dose of this medicine and it is within 8 hours of the usual time you take it, take it as soon as you remember. If you miss a dose and it has been more than 8 hours, skip the missed dose and take the next dose at the usual time. Do not take 2 doses at the same time.
Do not take a double dose to make up for missed doses.
If you stop taking Paxlovid
Even if you feel better, do not stop taking this medicine without talking to your doctor.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
Rare:may affect up to 1 in 1,000 people
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or blister after “EXP”. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Paxlovid Composition
Product Appearance and Package Contents
The 150 mg nirmatrelvir film-coated tablets are pink, oval in shape, and have "PFE" engraved on one side and "3CL" on the other.
The 100 mg ritonavir film-coated tablets are white to off-white, capsule-shaped, and have "H" engraved on one side and "R9" on the other.
Package for Twice-Daily Dosing Regimen
The Paxlovid film-coated tablets are presented in 5 blisters, one for each day, with a total of 30 tablets packaged in a cardboard box.
Each daily blister contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each) and indicates which tablets should be taken in the morning and at night (sun and moon symbols).
Package for Once-Daily Dosing Regimen
The Paxlovid film-coated tablets are presented in a 5-day blister with a total of 11 tablets packaged in a cardboard box.
The 5-day blister contains 6 nirmatrelvir tablets (150 mg each) and 5 ritonavir tablets (100 mg each) and indicates which tablets should be taken once daily for 5 days.
Only certain package sizes may be marketed.
Marketing Authorization Holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Brussels
Belgium
Manufacturer
Pfizer Manufacturing Deutschland GmbH
Mooswaldallee 1
79108 Freiburg Im Breisgau
Germany
Pfizer Italia S.r.L
Localita Marino del Tronto
63100 Ascoli Piceno
Italy
Pfizer Ireland Pharmaceuticals Unlimited Company
Little Connell
Newbridge
County Kildare
Ireland
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA Tel: +32 (0)2 554 62 11 | Latvija Pfizer Luxembourg SARL filiale Latvija Tel: + 371 670 35 775 |
Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +370 5 251 4000 | |
Ceská republika Pfizer, spol. s r.o. Tel: +420 283 004 111 | Magyarország Pfizer Kft. Tel.: + 36 1 488 37 00 |
Danmark Pfizer ApS Tlf.: +45 44 20 11 00 | Malta Vivian Corporation Ltd. Tel: +356 21344610 |
Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000 | Nederland Pfizer bv Tel: +31 (0)800 63 34 636 |
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500 | Norge Pfizer AS Tlf: +47 67 52 61 00 |
Ελλάδα Pfizer Ελλάς A.E. Τηλ: +30 210 6785800 | Österreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 |
España Pfizer, S.L. Tel: +34 91 490 99 00 | Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 00 |
France Pfizer Tél: +33 (0)1 58 07 34 40 | Portugal Laboratórios Pfizer, Lda. Tel: +351 21 423 5500 |
Hrvatska Pfizer Croatia d.o.o. Tel: +385 1 3908 777 | România Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 00 |
Ireland Pfizer Healthcare Ireland Unlimited Company Tel: 1800 633 363 (toll free) +44 (0)1304 616161 | Slovenija Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 400 |
Ísland Icepharma hf. Sími: +354 540 8000 | Slovenská republika Pfizer Luxembourg SARL, organizacná zložka Tel: + 421 2 3355 5500 |
Italia Pfizer S.r.l. Tel: +39 06 33 18 21 | Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 040 |
Κύπρος Pfizer Ελλάς Α.Ε. (Cyprus Branch) Τηλ: +357 22817690 | Sverige Pfizer AB Tel: +46 (0)8 550 520 00 |
Date of Last Revision of this Leaflet:05/2025.
Scan the code with a mobile device to obtain the leaflet in different languages.
URL: www.covid19oralrx.com
Other Sources of Information
Detailed information on this medication is available on the European Medicines Agency website: https://www.ema.europa.eu.
The leaflet can be found in all languages of the European Union/European Economic Area on the European Medicines Agency website.